Management Team
Heather Giles, Ph.D.
Interim President and CEO, Chief Scientific Officer
Dr. Giles has held international leadership positions in large and small pharmaceutical companies, and has wide experience in drug discovery and development from target validation, through clinical studies to final regulatory submission. She has expertise in numerous therapeutic areas and a track-record of delivering new drugs into development and on to market.
Dr. Giles joined Vapogenix in 2009 as Chief Scientific Officer and has provided scientific and drug development leadership, in addition to making significant contributions to overall company strategy and to successful fundraising. She was appointed Interim President, CEO and Director in July 2017.
Previously, from 2001 to 2008, she was Vice-President of Strategic Planning at Encysive, a small pharmaceutical company in Houston, Texas. There she managed the R&D portfolio and played a pivotal role in delivering the company’s key development product, to regulatory submission and subsequent European commercial launch. Prior to Encysive, Dr. Giles was International Disease Strategy Director for Asthma at GlaxoSmithKline R&D and prior to this was Head of the Receptor Pharmacology department at GlaxoWellcome R&D, UK (1995-2000). From 1983-1995, at Wellcome R&D, UK, she held various research, project leader and management positions.
She has an extensive scientific publication record and currently serves as adjunct Associate Professor in the Department of Pharmacology at the University of Houston. She is a member of the British Pharmacological Society and has served on their governing council and on the Editorial Board Editor for the British Journal of Pharmacology.
Interim President and CEO, Chief Scientific Officer
Dr. Giles has held international leadership positions in large and small pharmaceutical companies, and has wide experience in drug discovery and development from target validation, through clinical studies to final regulatory submission. She has expertise in numerous therapeutic areas and a track-record of delivering new drugs into development and on to market.
Dr. Giles joined Vapogenix in 2009 as Chief Scientific Officer and has provided scientific and drug development leadership, in addition to making significant contributions to overall company strategy and to successful fundraising. She was appointed Interim President, CEO and Director in July 2017.
Previously, from 2001 to 2008, she was Vice-President of Strategic Planning at Encysive, a small pharmaceutical company in Houston, Texas. There she managed the R&D portfolio and played a pivotal role in delivering the company’s key development product, to regulatory submission and subsequent European commercial launch. Prior to Encysive, Dr. Giles was International Disease Strategy Director for Asthma at GlaxoSmithKline R&D and prior to this was Head of the Receptor Pharmacology department at GlaxoWellcome R&D, UK (1995-2000). From 1983-1995, at Wellcome R&D, UK, she held various research, project leader and management positions.
She has an extensive scientific publication record and currently serves as adjunct Associate Professor in the Department of Pharmacology at the University of Houston. She is a member of the British Pharmacological Society and has served on their governing council and on the Editorial Board Editor for the British Journal of Pharmacology.
Clarice Motter, C.P.A., C.G.M.A.
Chief Financial Officer
Ms. Motter has over thirty years of experience in both public and privately held companies. She earned her M.B.A. from the UCLA Anderson School of Management and worked as an Auditor with KPMG prior to entering the private sector working in life science, manufacturing, service, and import/export industries. Ms. Motter has been involved with companies in all stages of development, including founding, pre-IPO, IPO, follow-on and M&A activities. She has been the CFO for many life science companies including: Ensysce BioSciences, Inc., N3D BioSciences, Inc., CorInnova Inc., LifeCell, Repros Chrysalis, BioTherapeutics, Inc., ProlX, and Aronex.
Chief Financial Officer
Ms. Motter has over thirty years of experience in both public and privately held companies. She earned her M.B.A. from the UCLA Anderson School of Management and worked as an Auditor with KPMG prior to entering the private sector working in life science, manufacturing, service, and import/export industries. Ms. Motter has been involved with companies in all stages of development, including founding, pre-IPO, IPO, follow-on and M&A activities. She has been the CFO for many life science companies including: Ensysce BioSciences, Inc., N3D BioSciences, Inc., CorInnova Inc., LifeCell, Repros Chrysalis, BioTherapeutics, Inc., ProlX, and Aronex.